
Cipla Ltd, country's fifth-largest drugmaker by sales, on Wednesday reported a 35 per cent fall in quarterly profit, missing analysts' estimates, mainly due to lower sales in the emerging markets and Europe.
Net profit in the July-September quarter was Rs 354 crore ($53.3 million), down from Rs 543 crore during the same period a year earlier. That compared with the average estimate of Rs 392 crore from analysts in a Thomson Reuters I/B/E/S poll.